Trial Profile
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 29 Nov 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2027.
- 29 Nov 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Sep 2027.
- 28 Sep 2023 Planned End Date changed from 30 Jun 2031 to 30 Sep 2023.